Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

LigoCyte

- PMLiVE

Takeda and Zinfandel abandon Alzheimer’s drug

Pioglitazone failed to show therapeutic improvements in late-stage testing

- PMLiVE

Takeda bags EU approval for Adcetris in lymphoma

Data shows the drug improves PFS and symptom burden in CTCL patients

- PMLiVE

Takeda ties-up with Denali Therapeutics for neuroscience boost

The companies will develop new therapies for conditions such as Alzheimer’s

- PMLiVE

Takeda offers €520m for stem cell firm TiGenix

The deal will go ahead if the Japanese pharma company can secure an 85% stake in the biotech

- PMLiVE

Takeda and SportInspired launch Active Communities, Brighter Future

The UK initiative will improve children's physical and mental wellbeing

EU flag

CHMP backs Europe’s first allogeneic stem cell therapy

Takeda has ex-US rights to the Crohn's disease treatment from biotech TiGenix

dengue fever mosquito

Sanofi confirms suspected safety issue with dengue vaccine

As rival Takeda conduct phase II testing for its own dengue vaccine candidate

- PMLiVE

Takeda Italia takes home digital innovation prize at Le Fonti Awards 2017

The pharmaceutical company wins award for its MyHospitalHub project

dengue fever mosquito

Takeda dengue vaccine data looks good as it chases Sanofi

TAK-003 achieved a 71% reduction in developing the virus compared to placebo

Eli Lilly HQ

Lilly expands its immuno-oncology work with $1.8bn CureVac deal

Will work with the German firm to develop ‘next generation’ cancer vaccines

Sanofi reception

Sanofi earmarks €170m for new French vaccines facility

Will expand its Val de Reuil production unit

- PMLiVE

Takeda can’t sway NICE on oral myeloma therapy Ninlaro

Drug not recommended for NHS use in England and Wales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links